No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX

byKathleen Lau

December 10, 2020

in StudyGraphics

#VisualAbstract: Increased incidence of sebaceous carcinomas among solid organ transplant recipients

RelatedReports

Nivolumab may be effective in platinum-resistant ovarian cancer

Surgery

Perioperative toripalimab improves event-free survival in non-small cell lung cancer

August 9, 2026

Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding

Chronic Disease

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

August 5, 2026

Adalimumab aids in control of noninfectious uveitis

Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026

Weekly Rewinds

2 Minute Medicine Rewind August 3rd, 2026

August 3, 2026

Oxygenated hypothermic perfusion reduces post-kidney transplant complications

Quick Take: Diffusion-weighted Imaging of Invasive Breast Cancer: Relationship to Distant Metastasis–free Survival

Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer

$#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma$

#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports